CA3213121A1 - Method of treating diseases using gremlin1 antagonists - Google Patents

Method of treating diseases using gremlin1 antagonists Download PDF

Info

Publication number
CA3213121A1
CA3213121A1 CA3213121A CA3213121A CA3213121A1 CA 3213121 A1 CA3213121 A1 CA 3213121A1 CA 3213121 A CA3213121 A CA 3213121A CA 3213121 A CA3213121 A CA 3213121A CA 3213121 A1 CA3213121 A1 CA 3213121A1
Authority
CA
Canada
Prior art keywords
seq
cancer
grem1
sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3213121A
Other languages
English (en)
French (fr)
Inventor
He ZHU
Xueming Qian
Weiqiang GAO
Chaping CHENG
Jinming WANG
Di SUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Transcenta Therapeutics Co Ltd
Shanghai Jiao Tong University
Original Assignee
Suzhou Transcenta Therapeutics Co Ltd
Shanghai Jiao Tong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Transcenta Therapeutics Co Ltd, Shanghai Jiao Tong University filed Critical Suzhou Transcenta Therapeutics Co Ltd
Publication of CA3213121A1 publication Critical patent/CA3213121A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3213121A 2021-03-11 2022-03-11 Method of treating diseases using gremlin1 antagonists Pending CA3213121A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021080142 2021-03-11
CNPCT/CN2021/080142 2021-03-11
CNPCT/CN2022/076516 2022-02-16
CN2022076516 2022-02-16
PCT/CN2022/080297 WO2022188856A1 (en) 2021-03-11 2022-03-11 Method of treating diseases using gremlin1 antagonists

Publications (1)

Publication Number Publication Date
CA3213121A1 true CA3213121A1 (en) 2022-09-15

Family

ID=83226314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3213121A Pending CA3213121A1 (en) 2021-03-11 2022-03-11 Method of treating diseases using gremlin1 antagonists

Country Status (11)

Country Link
US (1) US20240190950A1 (enExample)
EP (1) EP4304646A4 (enExample)
JP (1) JP2024513692A (enExample)
KR (1) KR20230156936A (enExample)
CN (1) CN116940380A (enExample)
AU (1) AU2022233762A1 (enExample)
BR (1) BR112023018204A2 (enExample)
CA (1) CA3213121A1 (enExample)
MX (1) MX2023010594A (enExample)
TW (1) TW202300527A (enExample)
WO (1) WO2022188856A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022152290A1 (en) * 2021-01-18 2022-07-21 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies
CN120957750A (zh) * 2023-04-13 2025-11-14 苏州创胜医药集团有限公司 用于治疗癌症的涉及grem1拮抗剂的组合疗法
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用
CN119746060B (zh) * 2025-03-07 2025-09-16 南昌大学第一附属医院 一种树突状细胞疫苗制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2826790B1 (en) * 2012-03-15 2019-02-13 SNU R&DB Foundation Anti-gremlin-1 antibody
EA201591762A1 (ru) * 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Человеческие антитела к grem1
CA3030582A1 (en) * 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
MX2020013808A (es) * 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
WO2022152290A1 (en) * 2021-01-18 2022-07-21 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies

Also Published As

Publication number Publication date
WO2022188856A1 (en) 2022-09-15
AU2022233762A1 (en) 2023-10-05
TW202300527A (zh) 2023-01-01
EP4304646A1 (en) 2024-01-17
KR20230156936A (ko) 2023-11-15
US20240190950A1 (en) 2024-06-13
CN116940380A (zh) 2023-10-24
EP4304646A4 (en) 2025-05-28
JP2024513692A (ja) 2024-03-27
BR112023018204A2 (pt) 2023-10-24
MX2023010594A (es) 2023-09-25

Similar Documents

Publication Publication Date Title
US20240360241A1 (en) Humanized antibodies that bind lgr5
US20240190950A1 (en) Method of treating diseases using gremlin1 antagonists
US11524074B2 (en) Cancer-cell-specific anti-TMEM-180 monoclonal antibody, anticancer drug, and cancer testing method
US20210115152A1 (en) Composition of bispecific antibodies and method of use thereof
WO2022152290A1 (en) Novel anti-gremlin1 antibodies
KR102644658B1 (ko) 모노클로날 항체 항-fgfr4
AU2017239038B2 (en) Administration of an anti-LGR5 monoclonal antibody
WO2021115303A1 (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
JP6041333B2 (ja) 抗腫瘍剤
WO2011007853A1 (ja) 癌特異的アイソフォームに対するモノクローナル抗体
JPWO2015186823A1 (ja) Ｆｏｌｒ１標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬
RU2853818C9 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
RU2853818C1 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
JPWO2016163433A1 (ja) 抗ｆｇｆｒ２抗体と他剤を含む組成物
HK40094175A (zh) 使用grem1拮抗剂治疗疾病的方法
TW202214251A (zh) 對抗癌劑之抵抗性改善劑
HK1234072B (en) Humanized antibodies that bind lgr5
HK1234072A1 (en) Humanized antibodies that bind lgr5

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250220

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250220

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260223

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260310

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260310

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260310